Cover Image

New opportunities for allergen immunotherapy using synthetic peptide immuno-regulatory epitopes (SPIREs)

Introduction: Allergen immunotherapy (AIT) reduces allergic rhinoconjunctivitis (ARC) symptoms, but long-term efficacy requires treatment for 3-5 years. Synthetic peptide immuno-regulatory epitopes, a new class of AIT, are allergen peptides with a shorter, more convenient treatment regimen that coul...

Full description

Saved in:
Bibliographic Details
Main Authors: Klimek, Ludger (Author) , Pfaar, Oliver (Author) , Worm, Margitta (Author)
Format: Article (Journal)
Language:English
Published: 13 Jun 2016
In: Expert review of clinical immunology
Year: 2016, Volume: 12, Issue: 10, Pages: 1123-1135
ISSN:1744-8409
DOI:10.1080/1744666X.2016.1189825
Online Access:Verlag, Volltext: https://doi.org/10.1080/1744666X.2016.1189825
Get full text
Author Notes:Ludger Klimek, Oliver Pfaar, Margitta Worm

MARC

LEADER 00000caa a2200000 c 4500
001 1668923572
003 DE-627
005 20230427221743.0
007 cr uuu---uuuuu
008 190710s2016 xx |||||o 00| ||eng c
024 7 |a 10.1080/1744666X.2016.1189825  |2 doi 
035 |a (DE-627)1668923572 
035 |a (DE-599)KXP1668923572 
035 |a (OCoLC)1341233484 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Klimek, Ludger  |d 1964-  |e VerfasserIn  |0 (DE-588)172705037  |0 (DE-627)697637476  |0 (DE-576)133562751  |4 aut 
245 1 0 |a New opportunities for allergen immunotherapy using synthetic peptide immuno-regulatory epitopes (SPIREs)  |c Ludger Klimek, Oliver Pfaar, Margitta Worm 
264 1 |c 13 Jun 2016 
300 |a 13 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 10.07.2019 
520 |a Introduction: Allergen immunotherapy (AIT) reduces allergic rhinoconjunctivitis (ARC) symptoms, but long-term efficacy requires treatment for 3-5 years. Synthetic peptide immuno-regulatory epitopes, a new class of AIT, are allergen peptides with a shorter, more convenient treatment regimen that could potentially have benefits on adherence and outcomes.Areas covered: Phase 2 trials of therapies derived from cat, house dust mite, grass, and ragweed allergen peptides demonstrated significant reduction in ARC symptoms after short-course treatment; improvement was sustained for 18-24 months posttreatment. We conducted a PubMed literature search for clinical publications using the search terms AIT; allergen peptides; ARC; cat, grass, house dust mite, and ragweed allergy; SCIT; SLIT; and synthetic peptides.Expert commentary: Long-term disease modification is a realistic goal of AIT. The inconvenience of conventional AIT regimens negatively impacts long-term persistence and, thus, efficacy. In comparison, SPIREs have a more convenient treatment regimen that could potentially have benefits on adherence and outcomes. 
650 4 |a Allergen immunotherapy 
650 4 |a allergen peptides 
650 4 |a cat allergy 
650 4 |a Der p 1 
650 4 |a Fel d 1 
650 4 |a grass allergy 
650 4 |a house dust mite allergy 
650 4 |a intradermal immunotherapy 
650 4 |a ragweed allergy 
650 4 |a SPIREs 
650 4 |a synthetic peptide immuno-regulatory epitopes 
700 1 |a Pfaar, Oliver  |d 1972-  |e VerfasserIn  |0 (DE-588)12385900X  |0 (DE-627)706454049  |0 (DE-576)293913099  |4 aut 
700 1 |a Worm, Margitta  |d 1964-  |e VerfasserIn  |0 (DE-588)12255552X  |0 (DE-627)705950131  |0 (DE-576)29332171X  |4 aut 
773 0 8 |i Enthalten in  |t Expert review of clinical immunology  |d Abingdon, Oxon : Taylor & Francis, 2005  |g 12(2016), 10, Seite 1123-1135  |h Online-Ressource  |w (DE-627)490222625  |w (DE-600)2191838-7  |w (DE-576)39810025X  |x 1744-8409  |7 nnas  |a New opportunities for allergen immunotherapy using synthetic peptide immuno-regulatory epitopes (SPIREs) 
773 1 8 |g volume:12  |g year:2016  |g number:10  |g pages:1123-1135  |g extent:13  |a New opportunities for allergen immunotherapy using synthetic peptide immuno-regulatory epitopes (SPIREs) 
856 4 0 |u https://doi.org/10.1080/1744666X.2016.1189825  |x Verlag  |x Resolving-System  |3 Volltext 
951 |a AR 
992 |a 20190710 
993 |a Article 
994 |a 2016 
998 |g 12385900X  |a Pfaar, Oliver  |m 12385900X:Pfaar, Oliver  |d 60000  |d 62100  |e 60000PP12385900X  |e 62100PP12385900X  |k 0/60000/  |k 1/60000/62100/  |p 2 
999 |a KXP-PPN1668923572  |e 3492450016 
BIB |a Y 
SER |a journal 
JSO |a {"note":["Gesehen am 10.07.2019"],"relHost":[{"id":{"zdb":["2191838-7"],"issn":["1744-8409"],"eki":["490222625"]},"part":{"volume":"12","text":"12(2016), 10, Seite 1123-1135","pages":"1123-1135","year":"2016","issue":"10","extent":"13"},"physDesc":[{"extent":"Online-Ressource"}],"note":["Gesehen am 01.09.15"],"origin":[{"publisher":"Taylor & Francis ; Informa Healthcare","dateIssuedDisp":"2005-","dateIssuedKey":"2005","publisherPlace":"Abingdon, Oxon ; London"}],"title":[{"title":"Expert review of clinical immunology","title_sort":"Expert review of clinical immunology"}],"pubHistory":["1.2005 -"],"type":{"media":"Online-Ressource","bibl":"periodical"},"disp":"New opportunities for allergen immunotherapy using synthetic peptide immuno-regulatory epitopes (SPIREs)Expert review of clinical immunology","recId":"490222625","language":["eng"]}],"physDesc":[{"extent":"13 S."}],"id":{"doi":["10.1080/1744666X.2016.1189825"],"eki":["1668923572"]},"type":{"bibl":"article-journal","media":"Online-Ressource"},"title":[{"title_sort":"New opportunities for allergen immunotherapy using synthetic peptide immuno-regulatory epitopes (SPIREs)","title":"New opportunities for allergen immunotherapy using synthetic peptide immuno-regulatory epitopes (SPIREs)"}],"language":["eng"],"person":[{"role":"aut","given":"Ludger","display":"Klimek, Ludger","family":"Klimek"},{"role":"aut","given":"Oliver","display":"Pfaar, Oliver","family":"Pfaar"},{"role":"aut","display":"Worm, Margitta","given":"Margitta","family":"Worm"}],"name":{"displayForm":["Ludger Klimek, Oliver Pfaar, Margitta Worm"]},"origin":[{"dateIssuedKey":"2016","dateIssuedDisp":"13 Jun 2016"}],"recId":"1668923572"} 
SRT |a KLIMEKLUDGNEWOPPORTU1320 

Similar Items